Skip to Main Content

Contribute Try STAT+ Today

patents

Most Read

Medication and money

First Opinion By Lyrissa Lidsky

Patent reform is needed to protect patients’ access to lifesaving drugs

Sen. Thom Tillis

First Opinion By Othman Laraki

Proposed patent legislation would block research, stifle innovation, and harm patients

Colorful book shelf

First Opinion By Peter Kolchinsky and Jessica Sagers

We need a Public Domain Day to highlight when drugs go off patent

George Church

In the Lab By Sharon Begley

In CRISPR patent fight, geneticist George Church may be called to testify

Feng Doudna

In the Lab By Sharon Begley

Lies, damn lies, and CRISPR: the legal battle escalates

Broad Institute building

Exclusive By Sharon Begley

CRISPR patent fight: The legal bills are soaring

Supreme Court

Politics By Dylan Scott

Supreme Court’s ruling in patent case a blow to drug industry

Pharmalot By Ed Silverman

India’s new patent policy spurs debate over implications for pharma

All Coverage

gavel pill background

Opinions+ By Andrei Iancu and David Kappos

Why does the FDA want to stop improving medicines via patent ‘areas of concern’?

Gender disparities in patents illo

Pharmalot By Ed Silverman

U.S. lawmakers accuse patent office of weakening challenges and allowing drug prices to rise

advertisement

Patent folder

Pharmalot By Ed Silverman

Advocates urge Biden to name patent office director that could transform drug pricing

MODERNA - Norwood facility

Pharmalot By Ed Silverman

Moderna vows not to enforce Covid-19 patents, but advocates say IP should be given to WHO

AbbVie California

Pharmalot By Ed Silverman

Consumer groups and unions urge FTC to block AbbVie and Allergan merger

Pharmalot By Ed Silverman

Pharmalittle: Judge appears to back push for opioid settlement; the CRISPR patent fight lives on

Alex Brandon/AP

Pharmalot By Ed Silverman

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

JOHNSON & JOHNSON HEADQUARTERS

Pharmalot By Ed Silverman

Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

Pharmalot By Ed Silverman

Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?

Pharmalot By Ed Silverman

Pharmalittle: NAFTA deal may hinge on patent protections for drugs; House committee goes after Sacklers

Pharmalot By Ed Silverman

Pharmalittle: Allergan depression drug fails three trials; Vertex CEO appears before Parliament

Pharmalot By Ed Silverman

Bristol-Myers faces growing opposition to its Celgene deal. Here’s what the wags are saying

Humira

Pharmalot By Ed Silverman

AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument

Len Schleifer

Pharma By Ed Silverman and Matthew Herper

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

Pharmalot By Ed Silverman

Pharmalittle: Drug makers to raise prices in January; Novartis names a new oncology chief, again

Drug costs

Pharmalot By Ed Silverman

Trump administration report would preclude reclaiming patents as a way to lower drug prices

Pharmalot By Ed Silverman

Pharmalittle: Retail drug spending in the U.S. fell last year; Democrats eye patents to lower drug prices

Pharmalot By Ed Silverman

Supreme Court to decide a patent case with big implications for small drug makers

Pharmalot By Ed Silverman

Pharmalittle: AbbVie cancer program’s setback; Amazon hires a pharmacy expert

German Pharma

Pharmalot By Ed Silverman

Boehringer Ingelheim abandons biosimilar sales outside the U.S.

Pharmalot By Ed Silverman

Pharmalittle: D.C. law firms prep pharma for a Democratic house; Allergan loses another battle over Restasis patent deal

Pharmalot By Ed Silverman

Pharmalittle: Trump hiring restrictions hurt FDA; Purdue family member has patent for addiction treatment

Tuberculosis patient

Pharmalot By Ed Silverman

U.N. global declaration on TB passes key hurdle as U.S. and others reach a compromise

Pharmalot By Ed Silverman

Allergan is urged to split CEO and chairman jobs by ‘disappointed’ hedge funds

Pharmalot By Ed Silverman

Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug